Docetaxel efficacy in prostate cancer is affected by testosterone; unraveling clinical observations

Autor:	Debra Stuurman, Alex Sparreboom, Ron H.J. Mathijssen, J.M. Moll, Mingqing Chen, C.M.A. De Ridder, L. Mout, Ashraf Aghai, Martijn P. Lolkema, Alice A. Gibson, W.M. Van Weerden, R. de Wit
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty Prostate cancer Docetaxel business.industry Urology Internal medicine medicine Testosterone (patch) business medicine.disease medicine.drug
Zdroj:	European Urology Supplements. 18:e3125
ISSN:	1569-9056
DOI:	10.1016/s1569-9056(19)33368-8
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6833f5c1367286ad1f8c09c71be596cf https://doi.org/10.1016/s1569-9056(19)33368-8 Zobrazit plný text záznamu Full Text from ScienceDirect